![We're fun to be around we promise!! Give us a call or stop in store for more information! #shopamelias | Boutique, Amelia, Lias We're fun to be around we promise!! Give us a call or stop in store for more information! #shopamelias | Boutique, Amelia, Lias](https://i.pinimg.com/736x/de/4f/99/de4f9947a9fc7b3092ee33419f02306e--a-call-to-be.jpg)
We're fun to be around we promise!! Give us a call or stop in store for more information! #shopamelias | Boutique, Amelia, Lias
![Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/db5c63dc-ee49-4b78-b05c-e93ffa8229af/gr1_lrg.jpg)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c0547203-d7c7-4471-bd9b-1440f4613981/gr1_lrg.jpg)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
![Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-022-28601-4/MediaObjects/41467_2022_28601_Fig6_HTML.png)
Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications
![Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-022-28601-4/MediaObjects/41467_2022_28601_Fig3_HTML.png)